AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. WCC
  4. [Form 4] Wesco International Inc. Insider Trading Activity

[Form 4] Wesco International Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (NASDAQ: ANTX) filed an 8-K disclosing an unregistered equity exchange with Coastlands Capital Partners LP. On 17 June 2025 and 19 June 2025, Coastlands returned a total of 2.8 million outstanding common shares (2.5 million + 0.3 million) to the company in exchange for an equal number of pre-funded warrants.

  • The warrants carry a $0.00001 exercise price and remain exercisable until fully exercised; they contain customary anti-dilution adjustments.
  • A 9.99% beneficial-ownership blocker (modifiable to 19.99% with 61-day notice) limits immediate voting concentration.
  • The transaction relied on the Securities Act 搂3(a)(9) exemption; therefore, no registration statement or cash consideration was involved.
  • Because the common shares are surrendered, basic share count and near-term dilution decrease until the warrants are exercised; fully-diluted share count is unchanged.

No other financial metrics, earnings data, or operational updates were provided.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) ha depositato un modulo 8-K divulgando uno scambio di azioni non registrato con Coastlands Capital Partners LP. Il 17 e il 19 giugno 2025, Coastlands ha restituito un totale di 2,8 milioni di azioni ordinarie in circolazione (2,5 milioni + 0,3 milioni) alla societ脿 in cambio di un numero equivalente di warrant pre-fondati.

  • I warrant hanno un prezzo di esercizio di $0,00001 e rimangono esercitabili fino al completo esercizio; includono aggiustamenti anti-diluizione consueti.
  • Un blocco di possesso beneficiario del 9,99% (modificabile al 19,99% con un preavviso di 61 giorni) limita la concentrazione immediata del voto.
  • La transazione si 猫 basata sull'esenzione prevista dalla Sezione 3(a)(9) del Securities Act; pertanto, non 猫 stata necessaria alcuna dichiarazione di registrazione n茅 猫 stato previsto alcun corrispettivo in denaro.
  • Poich茅 le azioni ordinarie sono state restituite, il conteggio base delle azioni e la diluizione a breve termine diminuiscono fino all'esercizio dei warrant; il conteggio completamente diluito rimane invariato.

Non sono stati forniti altri dati finanziari, risultati economici o aggiornamenti operativi.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) present贸 un formulario 8-K revelando un intercambio de acciones no registrado con Coastlands Capital Partners LP. El 17 y 19 de junio de 2025, Coastlands devolvi贸 un total de 2.8 millones de acciones comunes en circulaci贸n (2.5 millones + 0.3 millones) a la empresa a cambio de un n煤mero igual de warrants prefinanciados.

  • Los warrants tienen un precio de ejercicio de $0.00001 y permanecen ejercitables hasta que se ejerzan completamente; contienen ajustes anti-diluci贸n habituales.
  • Un l铆mite de propiedad beneficiosa del 9.99% (modificable al 19.99% con un aviso de 61 d铆as) limita la concentraci贸n inmediata de votos.
  • La transacci贸n se bas贸 en la exenci贸n de la Secci贸n 3(a)(9) de la Ley de Valores; por lo tanto, no se requiri贸 declaraci贸n de registro ni consideraci贸n en efectivo.
  • Dado que las acciones comunes se entregan, el conteo b谩sico de acciones y la diluci贸n a corto plazo disminuyen hasta que se ejerzan los warrants; el conteo totalmente diluido permanece sin cambios.

No se proporcionaron otros datos financieros, ganancias o actualizaciones operativas.

AN2 Therapeutics, Inc. (NASDAQ: ANTX)電� Coastlands Capital Partners LP鞕�鞚� 霌彪霅橃 鞎婌潃 欤检嫕 甑愴櫂鞚� 瓿奠嫓頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 6鞗� 17鞚缄臣 6鞗� 19鞚检棎 Coastlands電� 齑� 280毵� 欤检潣 氙胳儊頇� 氤错喌欤�(250毵� + 30毵� 欤�)毳� 須岇偓鞐� 氚橅櫂頃橁碃, 攴胳棎 靸侅潙頃橂姅 靷爠 鞛愱笀 臁半嫭 鞗岆煱韸�毳� 氚涭晿鞀惦媹雼�.

  • 鞗岆煱韸胳潣 頄夓偓臧�瓴╈潃 $0.00001鞚措┌ 鞕勳爠頌� 頄夓偓霅� 霑岅箤歆� 頄夓偓 臧�電ロ晿氅�, 鞚茧皹鞝侅澑 頋劃 氚╈ 臁办爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
  • 9.99%鞚� 鞁れ 靻岇湢甓� 彀嫧 鞛レ箻(61鞚� 靷爠 韱奠 鞁� 19.99%搿� 臁办爼 臧�電�)臧� 歃夑皝鞝侅澑 鞚橁舶甓� 歆戩鞚� 鞝滍暅頃╇媹雼�.
  • 鞚� 瓯半灅電� 歃濌秾氩� 搂3(a)(9) 氅挫牅毳� 攴缄卑搿� 頃橃榾鞙茧┌, 霐半澕靹� 霌彪 氇呾劯靹滊倶 順勱笀 雽�臧�臧� 韽暔霅橃 鞎婌晿鞀惦媹雼�.
  • 氤错喌欤缄皜 氚橅櫂霅棎 霐半澕 旮半掣 欤检嫕 靾橃檧 雼赴 頋劃鞚� 鞗岆煱韸� 頄夓偓 鞝勱箤歆� 臧愳唽頃橂┌, 鞕勳爠 頋劃 欤检嫕 靾橂姅 氤�頃橃 鞎婌姷雼堧嫟.

雼るジ 鞛 歆�響�, 靾橃澋 雿办澊韯� 霕愲姅 鞖挫榿 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�.

AN2 Therapeutics, Inc. (NASDAQ : ANTX) a d茅pos茅 un formulaire 8-K divulguant un 茅change d鈥檃ctions non enregistr茅 avec Coastlands Capital Partners LP. Les 17 et 19 juin 2025, Coastlands a restitu茅 un total de 2,8 millions d鈥檃ctions ordinaires en circulation (2,5 millions + 0,3 million) 脿 la soci茅t茅 en 茅change d鈥檜n nombre 茅gal de bons de souscription pr茅financ茅s.

  • Les bons ont un prix d鈥檈xercice de 0,00001 $ et restent exer莽ables jusqu鈥櫭� leur exercice complet ; ils comportent des ajustements anti-dilution habituels.
  • Un seuil de blocage de propri茅t茅 b茅n茅ficiaire de 9,99 % (modifiable 脿 19,99 % avec un pr茅avis de 61 jours) limite la concentration imm茅diate des droits de vote.
  • La transaction s鈥檈st appuy茅e sur l鈥檈xemption pr茅vue par la section 3(a)(9) du Securities Act ; par cons茅quent, aucune d茅claration d鈥檈nregistrement ni contrepartie en esp猫ces n鈥檃 茅t茅 impliqu茅e.
  • 脡tant donn茅 que les actions ordinaires sont restitu茅es, le nombre d鈥檃ctions de base et la dilution 脿 court terme diminuent jusqu鈥櫭� l鈥檈xercice des bons ; le nombre d鈥檃ctions enti猫rement dilu茅 reste inchang茅.

Aucune autre donn茅e financi猫re, r茅sultat ou mise 脿 jour op茅rationnelle n鈥檃 茅t茅 fournie.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) hat ein 8-K eingereicht, in dem ein nicht registrierter Aktientausch mit Coastlands Capital Partners LP offengelegt wird. Am 17. und 19. Juni 2025 gab Coastlands insgesamt 2,8 Millionen ausstehende Stammaktien (2,5 Millionen + 0,3 Millionen) an das Unternehmen zur眉ck und erhielt im Gegenzug eine gleiche Anzahl von vorausfinanzierten Warrants.

  • Die Warrants haben einen Aus眉bungspreis von 0,00001 $ und bleiben bis zur vollst盲ndigen Aus眉bung aus眉bbar; sie enthalten 眉bliche Verw盲sserungsschutzanpassungen.
  • Eine 9,99%ige Besitzblockade (mit 61-t盲giger Frist auf 19,99% anpassbar) begrenzt die unmittelbare Stimmrechtskonzentration.
  • Die Transaktion st眉tzte sich auf die Securities Act 搂3(a)(9)-Ausnahme; daher war keine Registrierungserkl盲rung oder Barzahlung erforderlich.
  • Da die Stammaktien zur眉ckgegeben wurden, verringert sich die Basisaktienzahl und die kurzfristige Verw盲sserung bis zur Aus眉bung der Warrants; die vollst盲ndig verw盲sserte Aktienzahl bleibt unver盲ndert.

Es wurden keine weiteren Finanzkennzahlen, Gewinnangaben oder operative Updates bereitgestellt.

Positive
  • Short-term reduction in basic outstanding shares may enhance EPS and float scarcity until warrants are exercised.
  • Beneficial-ownership blocker (9.99%) limits immediate concentration and potential control issues.
Negative
  • Future dilution overhang: the 2.8 million pre-funded warrants can be exercised at any time, restoring prior share count.
  • No cash inflow: transaction does not improve liquidity or fund operations.

Insights

TL;DR: 2.8 M shares swapped for pre-funded warrants; lowers current share count, neutral cash impact.

The exchange removes 2.8 million shares from the float, marginally improving per-share metrics in the short run. Because the warrants are already economically in-the-money and have an immaterial exercise price, the fully diluted share count and enterprise value are effectively unchanged. The 9.99% blocker reduces concentration risk and potential rapid resale pressure. However, the warrants represent an overhang that can be exercised at any time, limiting long-term benefit. No cash was raised, so the company鈥檚 liquidity position is unaffected. Overall impact is operationally neutral and modestly positive for short-term EPS optics.

TL;DR: Exchange uses 搂3(a)(9) to restructure insider holding; minimal governance impact.

By utilizing the 搂3(a)(9) exemption, AN2 avoided registration while re-papering Coastlands鈥� stake. The ownership cap aligns with standard governance safeguards, preventing instant control shifts above 9.99%. Because the warrants are non-voting until exercised, voting power is temporarily reduced, diffusing any single-holder influence. Yet, upon exercise (possible on two days鈥� notice), voting concentration could rebound to prior levels. From a governance standpoint, the mechanism is conventional and neither strengthens nor weakens shareholder rights materially.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) ha depositato un modulo 8-K divulgando uno scambio di azioni non registrato con Coastlands Capital Partners LP. Il 17 e il 19 giugno 2025, Coastlands ha restituito un totale di 2,8 milioni di azioni ordinarie in circolazione (2,5 milioni + 0,3 milioni) alla societ脿 in cambio di un numero equivalente di warrant pre-fondati.

  • I warrant hanno un prezzo di esercizio di $0,00001 e rimangono esercitabili fino al completo esercizio; includono aggiustamenti anti-diluizione consueti.
  • Un blocco di possesso beneficiario del 9,99% (modificabile al 19,99% con un preavviso di 61 giorni) limita la concentrazione immediata del voto.
  • La transazione si 猫 basata sull'esenzione prevista dalla Sezione 3(a)(9) del Securities Act; pertanto, non 猫 stata necessaria alcuna dichiarazione di registrazione n茅 猫 stato previsto alcun corrispettivo in denaro.
  • Poich茅 le azioni ordinarie sono state restituite, il conteggio base delle azioni e la diluizione a breve termine diminuiscono fino all'esercizio dei warrant; il conteggio completamente diluito rimane invariato.

Non sono stati forniti altri dati finanziari, risultati economici o aggiornamenti operativi.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) present贸 un formulario 8-K revelando un intercambio de acciones no registrado con Coastlands Capital Partners LP. El 17 y 19 de junio de 2025, Coastlands devolvi贸 un total de 2.8 millones de acciones comunes en circulaci贸n (2.5 millones + 0.3 millones) a la empresa a cambio de un n煤mero igual de warrants prefinanciados.

  • Los warrants tienen un precio de ejercicio de $0.00001 y permanecen ejercitables hasta que se ejerzan completamente; contienen ajustes anti-diluci贸n habituales.
  • Un l铆mite de propiedad beneficiosa del 9.99% (modificable al 19.99% con un aviso de 61 d铆as) limita la concentraci贸n inmediata de votos.
  • La transacci贸n se bas贸 en la exenci贸n de la Secci贸n 3(a)(9) de la Ley de Valores; por lo tanto, no se requiri贸 declaraci贸n de registro ni consideraci贸n en efectivo.
  • Dado que las acciones comunes se entregan, el conteo b谩sico de acciones y la diluci贸n a corto plazo disminuyen hasta que se ejerzan los warrants; el conteo totalmente diluido permanece sin cambios.

No se proporcionaron otros datos financieros, ganancias o actualizaciones operativas.

AN2 Therapeutics, Inc. (NASDAQ: ANTX)電� Coastlands Capital Partners LP鞕�鞚� 霌彪霅橃 鞎婌潃 欤检嫕 甑愴櫂鞚� 瓿奠嫓頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 6鞗� 17鞚缄臣 6鞗� 19鞚检棎 Coastlands電� 齑� 280毵� 欤检潣 氙胳儊頇� 氤错喌欤�(250毵� + 30毵� 欤�)毳� 須岇偓鞐� 氚橅櫂頃橁碃, 攴胳棎 靸侅潙頃橂姅 靷爠 鞛愱笀 臁半嫭 鞗岆煱韸�毳� 氚涭晿鞀惦媹雼�.

  • 鞗岆煱韸胳潣 頄夓偓臧�瓴╈潃 $0.00001鞚措┌ 鞕勳爠頌� 頄夓偓霅� 霑岅箤歆� 頄夓偓 臧�電ロ晿氅�, 鞚茧皹鞝侅澑 頋劃 氚╈ 臁办爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
  • 9.99%鞚� 鞁れ 靻岇湢甓� 彀嫧 鞛レ箻(61鞚� 靷爠 韱奠 鞁� 19.99%搿� 臁办爼 臧�電�)臧� 歃夑皝鞝侅澑 鞚橁舶甓� 歆戩鞚� 鞝滍暅頃╇媹雼�.
  • 鞚� 瓯半灅電� 歃濌秾氩� 搂3(a)(9) 氅挫牅毳� 攴缄卑搿� 頃橃榾鞙茧┌, 霐半澕靹� 霌彪 氇呾劯靹滊倶 順勱笀 雽�臧�臧� 韽暔霅橃 鞎婌晿鞀惦媹雼�.
  • 氤错喌欤缄皜 氚橅櫂霅棎 霐半澕 旮半掣 欤检嫕 靾橃檧 雼赴 頋劃鞚� 鞗岆煱韸� 頄夓偓 鞝勱箤歆� 臧愳唽頃橂┌, 鞕勳爠 頋劃 欤检嫕 靾橂姅 氤�頃橃 鞎婌姷雼堧嫟.

雼るジ 鞛 歆�響�, 靾橃澋 雿办澊韯� 霕愲姅 鞖挫榿 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�.

AN2 Therapeutics, Inc. (NASDAQ : ANTX) a d茅pos茅 un formulaire 8-K divulguant un 茅change d鈥檃ctions non enregistr茅 avec Coastlands Capital Partners LP. Les 17 et 19 juin 2025, Coastlands a restitu茅 un total de 2,8 millions d鈥檃ctions ordinaires en circulation (2,5 millions + 0,3 million) 脿 la soci茅t茅 en 茅change d鈥檜n nombre 茅gal de bons de souscription pr茅financ茅s.

  • Les bons ont un prix d鈥檈xercice de 0,00001 $ et restent exer莽ables jusqu鈥櫭� leur exercice complet ; ils comportent des ajustements anti-dilution habituels.
  • Un seuil de blocage de propri茅t茅 b茅n茅ficiaire de 9,99 % (modifiable 脿 19,99 % avec un pr茅avis de 61 jours) limite la concentration imm茅diate des droits de vote.
  • La transaction s鈥檈st appuy茅e sur l鈥檈xemption pr茅vue par la section 3(a)(9) du Securities Act ; par cons茅quent, aucune d茅claration d鈥檈nregistrement ni contrepartie en esp猫ces n鈥檃 茅t茅 impliqu茅e.
  • 脡tant donn茅 que les actions ordinaires sont restitu茅es, le nombre d鈥檃ctions de base et la dilution 脿 court terme diminuent jusqu鈥櫭� l鈥檈xercice des bons ; le nombre d鈥檃ctions enti猫rement dilu茅 reste inchang茅.

Aucune autre donn茅e financi猫re, r茅sultat ou mise 脿 jour op茅rationnelle n鈥檃 茅t茅 fournie.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) hat ein 8-K eingereicht, in dem ein nicht registrierter Aktientausch mit Coastlands Capital Partners LP offengelegt wird. Am 17. und 19. Juni 2025 gab Coastlands insgesamt 2,8 Millionen ausstehende Stammaktien (2,5 Millionen + 0,3 Millionen) an das Unternehmen zur眉ck und erhielt im Gegenzug eine gleiche Anzahl von vorausfinanzierten Warrants.

  • Die Warrants haben einen Aus眉bungspreis von 0,00001 $ und bleiben bis zur vollst盲ndigen Aus眉bung aus眉bbar; sie enthalten 眉bliche Verw盲sserungsschutzanpassungen.
  • Eine 9,99%ige Besitzblockade (mit 61-t盲giger Frist auf 19,99% anpassbar) begrenzt die unmittelbare Stimmrechtskonzentration.
  • Die Transaktion st眉tzte sich auf die Securities Act 搂3(a)(9)-Ausnahme; daher war keine Registrierungserkl盲rung oder Barzahlung erforderlich.
  • Da die Stammaktien zur眉ckgegeben wurden, verringert sich die Basisaktienzahl und die kurzfristige Verw盲sserung bis zur Aus眉bung der Warrants; die vollst盲ndig verw盲sserte Aktienzahl bleibt unver盲ndert.

Es wurden keine weiteren Finanzkennzahlen, Gewinnangaben oder operative Updates bereitgestellt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cameron James
(Last) (First) (Middle)
225 W STATION SQUARE DRIVE
SUITE 700
(Street)
PITTSBURGH PA 15219
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
WESCO INTERNATIONAL INC [ WCC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & GM, Util & Broadband
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 A 52.2552(1) A $0 56,030.9144 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents dividend equivalent rights ("DERs") in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on restricted stock units ("RSUs") held by the Reporting Person. Each DER is the economic equivalent of one share of Issuer's common stock and vests on the same schedule as the underlying award.
/s/ Michele Nelson, as Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many ANTX shares were exchanged for pre-funded warrants?

A total of 2,800,000 shares (2.5 M + 0.3 M) were swapped for warrants.

What is the exercise price of the AN2 Therapeutics pre-funded warrants?

Each warrant is exercisable at $0.00001 per share, effectively in-the-money.

Does the warrant exchange raise cash for AN2 Therapeutics?

No. The exchange was done under Securities Act 搂3(a)(9) with no cash consideration.

How does the transaction affect AN2 Therapeutics鈥� share count?

Basic shares outstanding drop by 2.8 M until the warrants are exercised; fully diluted share count is unchanged.

What ownership limits apply to the warrant holder?

The warrants include a 9.99% beneficial-ownership cap, adjustable up to 19.99% after 61 days鈥� notice.
Stock WCC logo
Wesco Intl

NYSE:WCC

WCC Rankings

#1420 Ranked by Market Cap
#1831 Ranked by Dividends

WCC Latest News

Jul 10, 2025
Wesco Announces Second Quarter 2025 Earnings Call
Jun 30, 2025
Wesco Publishes 2025 Sustainability Report
Jun 23, 2025
Wesco Announces Wesco Cares Champion of the Year Award Winner and Celebrates Annual Day of Caring
Jun 17, 2025
Wesco Announces the Promotion of Dirk Naylor to Executive Vice President and General Manager of Communications and Security Solutions
Jun 2, 2025
Wesco Ranks #199 in 2025 Fortune 500庐 List

WCC Latest SEC Filings

Jul 2, 2025
[Form 4] Wesco International Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Wesco International Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Wesco International Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Wesco International Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Wesco International Inc. Insider Trading Activity

WCC Stock Data

9.44B
47.80M
1.95%
97.21%
2.88%
Industrial Distribution
Wholesale-electrical Apparatus & Equipment, Wiring Supplies
United States
PITTSBURGH